Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts broadly favor Vor Biopharma: Eleven brokerages give the stock a consensus “Moderate Buy” rating, with an average 12-month price target of $43.38.
• Shares recently traded at $24.76, above their 50-day and 200-day moving averages, but well below the 52-week high of $49.95. The company’s latest quarterly loss of $0.80 per share was wider than analysts’ expected $0.69 loss.
• Institutional ownership stands at 97.29%, with several major investors increasing or initiating positions. Vor is developing gene-edited, off-the-shelf cell therapies, led by VOR33 for relapsed or refractory AML and high-risk MDS.

Shares of Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $43.3750.

A number of equities research analysts recently issued reports on the stock. Wedbush upped their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, August 12th. Weiss Ratings raised shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a research note on Tuesday, August 11th. HC Wainwright reiterated a "buy" rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Finally, Wall Street Zen raised shares of Vor Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th.

Vor Biopharma Price Performance

NASDAQ VOR opened at $24.76 on Thursday. The stock's fifty day moving average is $20.92 and its two-hundred day moving average is $16.93. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $49.95.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, research analysts anticipate that Vor Biopharma will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in VOR. Bank of America Corp DE grew its holdings in shares of Vor Biopharma by 679.3% during the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company's stock worth $232,000 after purchasing an additional 4,144 shares during the period. Squarepoint Ops LLC acquired a new position in Vor Biopharma in the third quarter valued at about $230,000. BNP Paribas Financial Markets boosted its stake in Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock worth $296,000 after buying an additional 5,058 shares during the period. Bridgeway Capital Management LLC purchased a new position in Vor Biopharma during the third quarter worth about $304,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new stake in shares of Vor Biopharma during the fourth quarter valued at about $134,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source